

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,837,242	11/1998	Holliger <i>et al.</i>			
	2	5,840,344	11/1998	Fukushima			
	3	5,885,574	03/1999	Elliott			
	4	6,126,980	10/2000	Smith <i>et al.</i>			
	5	6,579,692	06/2003	Fukushima			
	6	6,719,972	04/2004	Gribben <i>et al.</i>			
	7	6,759,043	07/2004	Fukushima			
	8	2003/0147894	08/2003	Fukushima <i>et al.</i>			
	9	2003/0157100	08/2003	Fukushima <i>et al.</i>			
	10	2003/0157577	08/2003	Fukushima <i>et al.</i>			
	11	2003/0202975	10/2003	Tedder			
	12	2003/0211108	11/2003	Fukushima <i>et al.</i>			
	13	2004/0001828	01/2004	Tuscano <i>et al.</i>			
	14	2004/0073013	04/2004	Fukushima <i>et al.</i>			
	15	2009/0022687	01/2009	Matsumoto <i>et al.</i>			
	16	2009/0028854	01/2009	Igawa <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	No
	17	EP 0 721 015	07/10/1996	Europe				
	18	EP 1 035 132	09/13/2000	Europe				
	19	EP 1 327 681	07/16/2003	Europe				
	20	EP 1 396 500	03/10/2004	Europe				
	21	EP 1 262 548	08/10/2008	Europe				
	22	JP 7236475	09/12/1995	Japan			Abstract only	
	23	JP 11-092500	04/06/1999	Japan			Abstract only	
	24	JP 2000-95800	04/04/2000	Japan			Abstract only	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	25	WO 91/16928	11/14/1991	WIPO				
	26	WO 92/19759	11/12/1992	WIPO			English abstract	
	27	WO 94/13806	06/23/1994	WIPO				
	28	WO 96/36360	11/21/1996	WIPO				
	29	WO 97/01633	01/16/1997	WIPO				
	30	WO 97/32601	09/12/1997	WIPO			English abstract	
	31	WO 98/44001	08/10/1998	WIPO				
	32	WO 99/17364	04/08/1999	WIPO				
	33	WO 00/53634	09/14/2000	WIPO			English abstract	
	34	WO 00/75191	12/14/2000	WIPO				
	35	WO 01/77342	10/18/2001	WIPO				
	36	WO 02/094880	11/28/2002	WIPO			English abstract	
	37	WO 02/097033	12/05/2002	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	38	AVENT <i>et al.</i> , "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific." <i>Biochem. J.</i> , 251:499-505 (1988)
	39	BARTLEY <i>et al.</i> , "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl." <i>Cell</i> , 77:1117-1124 (1994)
	40	BAZIL <i>et al.</i> , "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes." <i>Blood</i> , 86:502-511 (1995)
	41	BAZZONI <i>et al.</i> , "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(12):5376-5580 (1995)
	42	BERESFORD <i>et al.</i> , "Binding Characteristics and Tumor Targeting of a Covalently Linked Divalent CC49 Single-Chain Antibody." <i>Int. J. Cancer</i> , 81:911-917 (1999)
	43	BERGER <i>et al.</i> , "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)
	44	BODMER <i>et al.</i> , "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," <i>Nat. Cell Biol.</i> , 2:241-243 (2000)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	45	BOWIE <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310 (1990)	
	46	BROWN <i>et al.</i> , "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)	
	47	BROWN <i>et al.</i> , "Integrin-associated protein (CD47) and its ligands," <i>Trends Cell Biology</i> , 11(3):130-135 (2001)	
	48	BUCHSBAUM <i>et al.</i> , "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," <i>Clin. Cancer Res.</i> , 9:3731-3741 (2003)	
	49	BURGESS <i>et al.</i> , "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>J. Cell Biol.</i> , 111:2129-2138 (1990)	
	50	BURTHEM <i>et al.</i> , "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," <i>Blood</i> , 84(3):873-882 (1994)	
	51	CALDAS <i>et al.</i> , "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Mol. Immunol.</i> , 39:941-952 (2003)	
	52	CARON <i>et al.</i> , "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)	
	53	CHIEN <i>et al.</i> , "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 86:5532-5536 (1989)	
	54	CHIRGWIN <i>et al.</i> , "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> , 18(24):5294-5299 (1979)	
	55	CHUNTHARAPAI <i>et al.</i> "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> , 166:4891-4898 (2001)	
	56	COCHLOVIUS <i>et al.</i> , "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetraivalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," <i>Cancer Res.</i> , 60:4336-4341 (2000)	
	57	COOPER <i>et al.</i> , "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3978-3982 (1995)	
	58	DANIEL <i>et al.</i> , "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," <i>Human Immunology</i> , 65(3):189-199 (2004)	
	59	DE LEON <i>et al.</i> , "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," <i>BMC Cancer</i> , 9(48):1-9 (2009)	
	60	DEGLI-ESPOSTI <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> , 186:1165-1170 (1997)	
	61	DE SAUVAGE <i>et al.</i> , "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , 369:533-538 (1994)	
	62	DESPLANQ <i>et al.</i> , "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody BT2.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	63	DE ST. GROTH <i>et al.</i> , "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , 35:1-21 (1980)	
	64	DILLMAN, "Monoclonal antibodies for treating cancer," <i>Ann. Int. Med.</i> , 117(7):592-603 (1989)	
	65	DORAI <i>et al.</i> , "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)	
	66	EMERY <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> , 273:14363-14367 (1998)	
	67	FELGENHAUER <i>et al.</i> , "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , 18(16):4927 (1990)	
	68	FUJIMOTO <i>et al.</i> , "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," <i>Blood</i> , 86(6):2174-2182 (1995)	
	69	FUKUSHIMA <i>et al.</i> , "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," <i>Blood</i> , 80(8):1914-1922 (1992)	
	70	FUKUSHIMA <i>et al.</i> , "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," <i>Blood</i> , 94(10):479A (1999)	
	71	GALFRE <i>et al.</i> , "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)	
	72	GALFRE <i>et al.</i> , "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , 277:131-133 (1979)	
	73	GIUSTI <i>et al.</i> , "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)	
	74	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)	
	75	GREENSPAN <i>et al.</i> , "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)	
	76	GRELL <i>et al.</i> , "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," <i>Lymphokine and Cytokine Research</i> , 12(3):143-148 (1993)	
	77	GRIFFITH <i>et al.</i> , "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> , 162:2597-2605 (1999)	
	78	GUSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)	
	79	HOLLIGER <i>et al.</i> , "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)	
	80	HOPP <i>et al.</i> , "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)	
	81	HORAN <i>et al.</i> , "Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	82	HUSTON <i>et al.</i> , "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883 (1988)	
	83	ITOH <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991)	
	84	JIANG <i>et al.</i> , "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," <i>J. Biol. Chem.</i> , 280(6):4656-4662 (2005)	
	85	JONES <i>et al.</i> , "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," <i>Biotechnology</i> , 9:88-89 (1991)	
	86	KEARNEY, <i>et al.</i> , "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," <i>The Journal of Immunology</i> , 123(4):1548-1550 (1979)	
	87	KEEN <i>et al.</i> , "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," <i>Cytotechnology</i> , 18(3):207-217 (Abstract) (1994)	
	88	KIPRIYANOV <i>et al.</i> , "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," <i>In. J. Cancer</i> , 77:763-772 (1998)	
	89	KOHLER, <i>et al.</i> , "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519 (1976)	
	90	KORTT <i>et al.</i> , "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," <i>Eur. J. Biochem.</i> , 221:151-157 (1994)	
	91	KORTT <i>et al.</i> , "Single-chain Fv fragments of anti-neuramidase antibody NC10 containing five- and ten-residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423-433 (1997)	
	92	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)	
	93	LARRICK, <i>et al.</i> , "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)	
	94	LAW <i>et al.</i> , "Observations On The Effect Of A Folic-Acid Antagonist On Transplantable Lymphoid Leukemias In Mice," <i>Journal of the National Cancer Institute</i> , 10:179-193 (1949)	
	95	LAZAR <i>et al.</i> , "Transforming growth factor α : mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Molecular and Cellular Biology</i> , 8:1247-1252 (1988)	
	96	LEI <i>et al.</i> , "Characterization of the <i>Erwinia Carotovora</i> pelB Gene and Its Product Pectate Lyase," <i>Journal of Bacteriology</i> , 169:4379-4383 (1987)	
	97	LIN <i>et al.</i> , "Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon," <i>Biochemistry</i> , 14:1559-1563 (1975)	
	98	LINDBERG <i>et al.</i> , "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_5\beta_1$ -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
(37 CFR §1.98(b))		Filing Date April 18, 2007	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	99	LINDBERG <i>et al.</i> , "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," <i>J. Biol. Chem.</i> , 269:1567-1570 (1994)	
	100	MARGULIES <i>et al.</i> , "Somatic Cell Hybridization of Mouse Myeloma Cells," <i>Cell</i> , 8:405-415 (1976)	
	101	MARIUZZA <i>et al.</i> , "The Structural Basis of Antigen-Antibody Recognition," <i>Ann. Rev. Biophys. Biophys. Chem.</i> , 16:139-159 (1987)	
	102	MARSTERS <i>et al.</i> , "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," <i>Curr. Biol.</i> , 7:1003-1006 (1997)	
	103	MATEO <i>et al.</i> , "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," <i>FASEB Journal</i> , 12(5):A1082 (1998)	
	104	MAWBY <i>et al.</i> , "Isolation and characterization of CD47 glycoprotein: a multispansing membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," <i>Biochem. J.</i> , 304:525-530 (1994)	
	105	METHIA <i>et al.</i> , "Oligodeoxynucleotides Antisense to the Proto-Oncogene c-Mpl Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> , 82(5):1395-1401 (1993)	
	106	MILILI <i>et al.</i> , "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," <i>Eur. J. Immunol.</i> , 26:63-69 (1996)	
	107	MIZUSHIMA <i>et al.</i> , "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> , 18(17):5322 (1990)	
	108	MOORE <i>et al.</i> , "Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor," <i>Biochemistry</i> , 38:13960-13967 (1999)	
	109	MORI <i>et al.</i> , "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death and Differentiation</i> , 11:203-207 (2004)	
	110	MULLIGAN <i>et al.</i> , "Synthesis of Rabbit β-Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 β-Globin Recombinant Genome," <i>Nature</i> , 277:108-114 (1979)	
	111	NAKAYAMA <i>et al.</i> , "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)	
	112	NGO <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr. <i>et al.</i> Editors, Birkhauser Boston, 433-506 (1994)	
	113	O'BRIEN <i>et al.</i> , "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> , 14(6):1021-1023 (1986)	
	114	OHTSUKA <i>et al.</i> , "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," <i>Oncogene</i> , 22:2034-2044 (2003)	
	115	PAN <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818 (1997)	
	116	PAN <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113 (1997)	
	117	PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Chapter 8, p. 242 (1993)	
	118	PETTERSON <i>et al.</i> , "CD47 Signals T Cell Death," <i>J. Immunol.</i> , 7031-7040 (1999)	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	119	PETTERSON, "CD47 and death signaling in the immune system," <i>Apoptosis</i> , 5:299-306 (2000)	
	120	REINHOLD <i>et al.</i> , "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," <i>J. Cell Science</i> , 108:3419-3425 (1995)	
	121	RIECHMANN <i>et al.</i> , "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 332:323-327 (1988)	
	122	REITTER <i>et al.</i> , "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," <i>Protein Engineering</i> , 7(5):697-704 (1994)	
	123	REITER <i>et al.</i> , "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," <i>Biochemistry</i> , 33:5451-5459 (1994)	
	124	ROUE <i>et al.</i> , "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," <i>Biochimie</i> , 85:741-746 (2003)	
	125	ROZSNAY <i>et al.</i> , "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> , 37(2-3):197-205 (1993)	
	126	SATO <i>et al.</i> , "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Research</i> , 53:851-856 (1993)	
	127	SCHICKEL, <i>et al.</i> , "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," <i>Biochem. Cell. Biol.</i> , 80(2):169-176 (2002)	
	128	SCHWARTZ <i>et al.</i> , "A superactive insulin: [B10-aspartic acid]insulin(human)," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:6408-6411 (1987)	
	129	SCHWARTZ <i>et al.</i> , "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," <i>J. Biol. Chem.</i> , 268(27):19931-19934 (1993)	
	130	SCHMIDT <i>et al.</i> , "A bivalent single-chain antibody-toxin specific for Erbb-2 and the EGF receptor," <i>Int. J. Cancer</i> , 65(4):538-546 (1996)	
	131	SHERIDAN <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> , 277:818-821 (1997)	
	132	SHIGETA <i>et al.</i> , "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," <i>Clin. Exp. Immunol.</i> , 42:458-462 (1980)	
	133	SHULMAN <i>et al.</i> , "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-270 (1978)	
	134	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)	
	135	SPAARGAREN <i>et al.</i> , "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>The J. Biol. Chem.</i> , 266(3):1733-1739 (1981)	
	136	STANCOVSKI <i>et al.</i> , "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695 (1991)	
	137	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," <i>J. Exp. Med.</i> , 148:313-323 (1978)	
	138	VAN GEELEN <i>et al.</i> , "Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines," <i>Br. J. Cancer</i> , 89(2):363-373 (2003)	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	139	VERMA <i>et al.</i> , "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216:165-181 (1998)	
	140	WALCZAK <i>et al.</i> , "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397 (1997)	
	141	WELLS, "Perspectives in Biochemistry," <i>Biochemistry</i> , 29(37):8509-8517 (1990)	
	142	WILEY <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> , 3:673-682 (1995)	
	143	WINKLER <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> , 265:4505-4514 (2000)	
	144	XIE <i>et al.</i> , "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," <i>Nature Biotechnology</i> , 15(8):768-771 (1997)	
	145	YANABU <i>et al.</i> , "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein lb monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)	
	146	YARDEN <i>et al.</i> , "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> , 26(5):1434-1442 (1987)	
	147	YELTON <i>et al.</i> , "Fusion of Mouse Myeloma and Spleen Cells," <i>Current Topics in Microbiology and Immunology</i> , 81:1-7 (1978)	
	148	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages	
	149	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page	
	150	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages	
	151	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages	
	152	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages	
	153	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages	
	154	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated August 8, 2007 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages	
	155	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 4 pages	
	156	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages	
	157	FISH & RICHARDSON, Amendment in Reply to Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages	
	158	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages	
	159	FISH & RICHARDSON, Amendment in Reply to Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages	
	160	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/013063, mailed November 18, 2003, 2 pages	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	161	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages	
	162	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages	
	163	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages	
	164	U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages	
	165	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page	
	166	U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages	
	167	FISH & RICHARDSON P.C., Reply to Office Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages	
	168	U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages	
	169	U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages	
	170	U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages	
	171	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages	
	172	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages	
	173	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages	
	174	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/550,934, mailed November 21, 2007, 7 pages	
	175	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 21, 2007 in U.S. App. Ser. No. 10/550,934, filed April 16, 2008, 2 pages	
	176	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed June 12, 2008, 27 pages	
	177	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 12, 2008 in U.S. App. Ser. No. 10/550,934, filed December 12, 2008, 45 pages	
	178	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/550,934, mailed March 16, 2009, 19 pages	
	179	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696, mailed July 27, 2004, 5 pages	
	180	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/004696, dated February 9, 2005, 10 pages	
	181	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated March 31, 2006, 4 pages	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	182	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed June 27, 2008, 6 pages	
	183	FISH & RICHARDSON P.C., Response to Restriction Requirement dated June 27, 2008 in U.S. App. Ser. No. 10/551,504, filed September 29, 2008, 13 pages	
	184	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed December 16, 2008, 5 pages	
	185	FISH & RICHARDSON P.C., Response to Restriction Requirement dated December 16, 2008 in U.S. App. Ser. No. 10/551,504, filed December 23, 2008, 14 pages	
	186	U.S. EXAMINER LORRAINE SPECTOR, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/551,504, mailed April 15, 2009, 35 pages	
	187	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506, mailed March 22, 2005, 3 pages	
	188	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages	
	189	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser. No. EP 04 82 0316, dated July 17, 2008, 3 pages	
	190	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages	
	191	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages	
	192	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed January 4, 2008, 8 pages	
	193	FISH & RICHARDSON P.C., Response to Restriction Requirement dated January 4, 2008 in U.S. App. Ser. No. 10/582,413, filed February 4, 2008, 2 pages	
	194	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,413, mailed March 31, 2008, 17 pages	
	195	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 31, 2008 in U.S. App. Ser. No. 10/582,413, filed June 30, 2008, 20 pages	
	196	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed June 30, 2008, 2 pages	
	197	U.S. EXAMINER BRADLEY DUFFY, USPTO Notice of Informal or Non-Responsive Amendment in U.S. App. Ser. No. 10/582,413, mailed October 20, 2008, 3 pages	
	198	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 12, 2008, 4 pages	
	199	FISH & RICHARDSON P.C., Amendment in Reply to Notice of Informal or Non-Responsive Amendment dated October 20, 2008 in U.S. App. Ser. No. 10/582,413, filed November 17, 2008, 10 pages	
	200	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 25, 2008, 4 pages	
	201	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 24, 2008, 4 pages	
	202	U.S. EXAMINER BRADLEY DUFFY, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed March 11, 2009, 8 pages	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	203	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 11, 2009 in U.S. App. Ser. No. 10/582,413, filed April 8, 2009, 8 pages	
	204	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed June 25, 2009, 28 pages	
	205	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages	
	206	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages	
	207	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser. No. EP 04 82 0305, dated October 6, 2008, 3 pages	
	208	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,304, mailed November 20, 2008, 7 pages	
	209	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 20, 2008 in U.S. App. Ser. No. 10/582,304, filed December 16, 2008, 3 pages	
	210	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed April 1, 2009, 38 pages	
	211	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated April 1, 2009 in U.S. App. Ser. No. 10/582,304, filed June 30, 2009, 15 pages	
	212	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018501, mailed March 29, 2005, 2 pages	
	213	JAPANESE EXAMINER YOSHIO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018501, dated November 4, 2005, 7 pages	
	214	EPO EXAMINER HELENA DOMINGUES, European Search Report for App. Ser. No. EP 04 82 0311, dated January 28, 2009, 4 pages	
	215	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages	
	216	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages	
	217	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages	
	218	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages	
	219	U.S. EXAMINER ELLY GERALD STOICA, USPTO Restriction Requirement in U.S. App. Ser. No. 11/913,229, mailed July 8, 2009, 6 pages	
	220	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890, mailed July 18, 2006, 2 pages	
	221	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/309890, dated November 19, 2007, 5 pages	
	222	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,654, mailed May 26, 2009, 9 pages	
	223	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser. No. 10/399,518, mailed November 25, 2005, 9 pages	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	224	FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S. App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages	
	225	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed March 27, 2006, 38 pages	
	226	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed September 26, 2006, 26 pages	
	227	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages	
	228	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages	
	229	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed December 28, 2006, 29 pages	
	230	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App. Ser. No. 10/399,518, filed May 3, 2007, 22 pages	
	231	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed June 7, 2007, 13 pages	
	232	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages	
	233	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed September 27, 2007, 5 pages	
	234	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser. No. 10/399,518, mailed November 13, 2007, 3 pages	
	235	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed January 31, 2008, 14 pages	
	236	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App. Ser. No. 10/399,518, filed April 30, 2008, 7 pages	
	237	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed August 4, 2008, 8 pages	
	238	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed November 7, 2008, 4 pages	
	239	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App. Ser. No. 10/399,518, filed October 23, 2008, 8 pages	
	240	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed February 17, 2009, 12 pages	
	241	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App. Ser. No. 10/399,518, filed May 18, 2009, 26 pages	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	